Swiss biotechnology startup HAYA Therapeutics announces collaboration with Lilly

Discovery of novel regulatory genomic targets for obesity and related metabolic conditions using proprietary RNA platform

09-Sep-2024 - HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug ...

Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany

Company also commits to investing up to $100 million in German early-stage life sciences ecosystem

20-Nov-2023 - Eli Lilly and Company announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company's global parenteral (injectable) product and device manufacturing network and support an increased demand ...

Triastek announces research collaboration with Lilly

Application of 3D printing technology in oral delivery of drugs

19-Jul-2022 - Triastek, Inc. announced a collaboration with Eli Lilly and Company to leverage the advantages of 3D printing technology to enable precisely targeted and programmed release of drugs in specific regions of the GI tract. According to the agreement, the project will focus on the targeted release of ...

Evotec and Lilly enter into drug discovery collaboration in metabolic diseases

Lilly has the right to select up to five programmes

19-Jan-2022 - Evotec SE announced that the Company has entered into a drug discovery collaboration with Eli Lilly and Company in the field of metabolic diseases with a focus on kidney diseases and diabetes. The collaboration leverages Evotec’s extensive experience and track record of delivering in the field ...

Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

CureVac to receive an upfront payment of $50 million and an equity investment of €45 million

19-Oct-2017 - Eli Lilly and Company and CureVac AG have announced a global immuno-oncology collaboration focused on the development and commercialization of up to five potential cancer vaccine products based on CureVac’s proprietary RNActive® technology. The companies will use messenger RNA (mRNA) technology ...

Major pharma companies sign up to groundbreaking Parkinson's consortium

25-Feb-2016 - Seven of the world's largest pharmaceutical companies have signed up to a groundbreaking consortium aimed at accelerating the development of safe and effective therapies for Parkinson's. The Critical Path for Parkinson's consortium will bring together leading academics; industry members AbbVie, ...

Lilly Announces Diabetes Research Partnership with University of Surrey

29-Dec-2014 - Eli Lilly and Company announced a five-year research partnership with the University of Surrey to study health outcomes, focusing on the effects of treatment in people with type 2 diabetes, which affects about 95 percent of those with the disease.Using real-world evidence (routine data gathered ...

QIAGEN announces third co-development program for companion diagnostics paired with Lilly’s investigational cancer compounds

21-Nov-2013 - QIAGEN announced an agreement with Eli Lilly and Company to develop and commercialize a molecular companion diagnostic paired with a novel Lilly oncology compound. This is the third co-development project by QIAGEN and Lilly to create companion diagnostics, which are tests that analyze genomic ...

Lilly Announces Withdrawal of Xigris Following Recent Clinical Trial Results

27-Oct-2011 - Eli Lilly and Company announced withdrawal of its Xigris® [drotrecogin alfa (activated)] product in all markets following results of the PROWESS-SHOCK study, which showed the study did not meet the primary endpoint of a statistically significant reduction in 28-day all-cause mortality in patients ...

Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases

The Lilly NCD Partnership will seek innovative solutions to help fight chronic diseases in developing countries

15-Sep-2011 - Eli Lilly and Company announced today a $30 million commitment over five years to fight the rising burden of non-communicable diseases in developing nations. Lilly is launching The Lilly NCD Partnership, which combines the company's unique resources with the expertise of leading global health ...